Background/Aims: Human mutL homolog 1 (MLH1) promoter methylation was reported in gastric cancer (GC). This study determined the clinicopathological, prognostic, and diagnostic effects of MLH1 promoter methylation in GC. Methods: The combined odds ratio (OR) or hazard ratio (HR) and their corresponding 95% confidence intervals (95% CI) were calculated. The pooled sensitivity, specificity, and area under the curve (AUC) were analyzed. Results: A total of 4654 GC patients and 3669 non-malignant controls were identified in this systematic analysis. MLH1 promoter methylation was significantly higher in GC samples than in gastric adenomas, chronic gastritis, adjacent tissues, normal gastric mucosa, and normal healthy blood samples, but it exhibited a similar frequency in GC vs. intestinal metaplasia and dysplasia samples. MLH1 promoter methylation correlated with age and microsatellite instability (MSI), but it was not associated with gender, H. pylori infection, smoking, drinking behaviors, pathological histology, tumor differentiation, clinical stage, lymph node status, distant metastasis, or overall survival of GC. MLH1 promoter methylation exhibited a poor sensitivity value (< 0.5) in patients with GC compared with adjacent tissues, gastric adenomas, chronic gastritis, normal gastric mucosa, and normal healthy blood samples. The pooled sensitivity, specificity, and AUC of MLH1 promoter methylation in GC with MSI vs. GC with microsatellite stability (MSS) samples were 0.64, 0.96, and 0.90, respectively. Conclusions: Our results suggest that the detection of MLH1 promoter methylation may be a potential prognostic biomarker for GC patients with MSI.
Introduction
Gastric cancer (GC) is one of the most common malignant tumors and the third leading cause of death from human cancers. An estimated 951, 600 new cases of GC were clinically diagnosed worldwide in 2012, which led to approximately 723, 100 deaths due to GC [1] . Lauren's classification identifies two main histotypes of GC, intestinal and diffuse [2] . GC patients remain a primary clinical challenge despite recent improvements in the diagnostic, surgical, and therapeutic opportunities for GC [3, 4] .
Increasing evidence reveals that a common epigenetic modification, DNA methylation, plays a crucial role in cancer carcinogenesis, progression, and prognosis [5] [6] [7] . Helicobacter pylori (H. pylori) infection and microsatellite instability (MSI) are associated with an increased risk of developing GC [8, 9] . Human mutL homolog 1 (MLH1) gene is located on chromosome 3p21 and encodes a DNA mismatch repair (MMR) protein [10] . DNA MMR genes have important functions in the maintenance of genome stability. Therefore, loss of MMR function leads to MSI, which contributes to the development of gastric carcinoma [11, 12] . MLH1 promoter methylation in sporadic tumors may primarily cause MSI [13] . MSI in GC is frequent because MLH1 promoter methylation within CpG islands inactivates the MLH1 gene [14, 15] . The presence of MLH1 promoter methylation is widely reported in GC [16] [17] [18] [19] .
Numerous studies reported a relationship between MLH1 promoter methylation and GC risk, but the results of these articles are inconsistent and conflicting. For example, Lee et al. reported that MLH1 promoter methylation exhibited a similar frequency in GC and gastric adenomas [20] , and Kang et al. demonstrated that MLH1 promoter methylation exhibited a higher frequency in GC than in gastric adenomas [21] . Therefore, the current study evaluated the association between MLH1 promoter methylation and the risk of GC in cancer vs. different control groups: gastric adenomas, intestinal metaplasia, chronic gastritis, dysplasia, adjacent to cancer, normal gastric mucosa, and normal healthy blood samples. We evaluated the correlation of MLH1 promoter methylation with the clinicopathological characteristics of GC and its prognostic role. We also analyzed whether MLH1 promoter methylation could be used as a biomarker for the diagnosis of GC.
Materials and Methods
Literature search A comprehensive literature search was performed to identify eligible studies published before January 3, 2017, in the following online electronic databases: PubMed, Embase, Cochrane library, and EBSCO. We used the following combined key words and terms: (stomach OR gastric) AND (cancer OR tumor OR neoplasm OR carcinoma) AND (MLH1 OR hMLH1 OR mutL homolog 1 OR human mutL homolog 1) AND (methylation OR epigenetic silencing OR epigenetic inactivation OR hypermethylation). We also scanned the references of eligible articles for additional studies.
Inclusion criteria
The following inclusion criteria were used to select eligible studies for the meta-analysis: 1) all cancer samples were diagnosed as primary GC using histopathological identification; 2) studies included sufficient data on MLH1 promoter methylation to assess the correlation between GC and non-malignant controls; 3) the control groups consisted of gastric adenomas, intestinal metaplasia, chronic gastritis, dysplasia, adjacent to cancer, normal gastric mucosa, and normal healthy blood samples; 4) studies provided sufficient information to evaluate the relationship between MLH1 promoter methylation and the clinicopathological characteristics of GC patients; 5) studies provided prognostic analyses on overall survival (OS) or diseasefree survival (DFS) if possible; and 6) studies were published in English. The more complete papers with more information were selected when authors published multiple papers using duplicated sample data. 
Data extraction

Statistical analysis
All data were analyzed using Stata 12.0 software (Stata Corporation, College Station, TX, USA). The combined odds ratio (OR) and corresponding 95% confidence interval (95% CI) were calculated to evaluate the relationship between MLH1 promoter methylation and GC in cancer vs. different control groups and the correlation between MLH1 promoter methylation and the clinicopathological parameters of GC. The pooled hazard ratio (HR) and the 95% CI were also calculated to analyze the clinical outcome of MLH1 promoter methylation in GC patients where possible. Heterogeneity of this meta-analysis was detected using the Cochran's Q statistic [22, 23] . A random-effects model was used for the meta-analysis. Significant heterogeneity was considered for a P value less than 0.1 for the Q statistic. A sensitivity analysis for positive results was performed by omitting a single study to determine the stability of the pooled results [24, 25] . Publication bias was analyzed using the Egger linear regression test for results with greater than nine studies [26] . Pooled sensitivity, specificity, and area under the curve (AUC) were performed using bivariate analysis to evaluate the diagnostic role of MLH1 promoter methylation in GC [27, 28] . Fig. 1 shows that careful scanning using the inclusion criteria yielded 62 studies published from 1999 to 2016 [15] [16] [17] [18] [19] [20] [21] , including 4654 patients with GC and 3669 non-malignant controls. Twenty-nine studies involving 2583 GC patients and 2396 adjacent tissue samples evaluated the association between MLH1 promoter methylation and GC [18-20, 30-33, 36, 40, 41, 49, 50, 55, 56, 59, 61-63, 65, 67, 68, 70, 73, 74, 76, 78, 80-82] . Seven studies with 409 GC patients Table S1 lists the general information of the included studies. Fig. 2 shows that the level of MLH1 promoter methylation was significantly increased in GC samples compared to adjacent tissue samples (OR = 5.50, 95% CI = 3.41-8.86, P < 0.001).
Results
Study characteristics
Association between MLH1 promoter methylation and GC in cancer vs. adjacent tissues
Subgroup analyses were performed based on the detection method ((methylation-specific polymerase chain reaction (MSP) and non-MSP)) and ethnicity (Asian, Caucasian, and mixed populations) to assess the strength of the associations between different subgroups (Table 1) . Subgroup analysis based on ethnicity demonstrated that MLH1 promoter methylation correlated with GC in Asian, Caucasian, and mixed populations (OR = 4.98, 95% CI = 2.69-9.21, P < 0.001; OR = 6.51, 95% CI = 2.68-15.79, P < 0.001; OR = 14.32, 95% CI = 1.79-114.60, P = 0.012; respectively).
Subgroup analysis by the detection method revealed that MLH1 promoter methylation was associated with GC in the MSP and non-MSP methods (OR = 5.38, 95% CI = 3.07-9.42, P < 0.001; OR = 4.41, 95% CI = 2.29-8.47, P < 0.001; respectively).
Substantial heterogeneity was measured in the comparison of cancer and adjacent tissue samples (P < 0.001). Therefore, we successively removed seven studies ( [31, 40, 61, 62, 68, 73, 74] ). The recalculated OR was 7.02 (95% CI = 4.44-11.10, P < 0.001) with no heterogeneity (P = 0.310).
Association between MLH1 promoter methylation and GC in cancer vs. benign lesions MLH1 promoter methylation in GC was notably higher than that in gastric adenoma or chronic gastritis (OR = 2.44, 95% CI = 1.36-4.39, P = 0.003; OR = 8.78, 95% CI = 4.52-17.05, (Fig. 4) .
Association between MLH1 promoter methylation and gender
Data from 28 studies of 2576 GC patients demonstrated that MLH1 promoter methylation did not correlate with the gender of GC patients (male vs. female: OR = 0.73, 95% CI = 0.51-1.06, P = 0.097) (Fig. 5) .
Heterogeneity was high (P = 0.001), and three studies (47, 54, 73] ) were successively removed. The overall OR was recalculated (OR = 0.76, 95% CI = 0.57-1.02, P = 0.064), and the P value of heterogeneity was 0.190.
Association between MLH1
promoter methylation and age of GC patients Data from 13 studies of 712 GC patients demonstrated that MLH1 promoter methylation correlated with patient age (OR = 1.72, 95% CI = 1.14-2.60, P = 0.01) (Fig. 6) . (Fig. 6) .
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Association between MLH1 promoter methylation and tumor differentiation or GC stage
No correlation was observed between MLH1 promoter methylation and tumor differentiation or clinical stage (OR = 1.12, 95% CI = 0.67-1.89, P = 0.658; OR = 1.12, 95% CI = 0.68-1.82, P = 0.66; respectively) ( Fig. 7) , including eight studies of 561 GC patients and nine studies of 562 GC patients, respectively.
Association between MLH1 promoter methylation and lymph node status or distant metastasis of GC MLH1 promoter methylation did not correlate with lymph node status or distant metastasis (OR = 1.04, 95% CI = 0.71-1.50, P = 0.852; OR = 1.49, 95% CI = 0.86-2.60, P = 0.157; respectively) ( Fig.  8) , including 18 studies with 1954 GCs and 10 studies with 1493 GCs, respectively. (Fig. 10) .
Prognostic effect of MLH1 promoter methylation
Only two studies (143 GCs) investigated MLH1 promoter methylation and prognosis and reported that MLH1 promoter methylation did not correlate with patient prognosis of OS (data not shown) [53, 56] .
Publication bias
The potential publication bias was measured in the comparison of GC and adjacent tissues, in gender, age factor, lymph node status, distant metastasis, tumor histology, and microsatellite status (see online suppl. material, Fig. S1 ). There was evidence of publication bias in GC vs. adjacent tissue samples and tumor histology (P < 0.05). No publication bias was found between MLH1 promoter methylation and other clinicopathological features (P > 0.1). 11) . These values of sensitivity, specificity, and AUC (sensitivity = 0.64 > 0.5, specificity = 0.96 > 0.9, and AUC = 0.90 ≥ 0.9) suggest that MLH1 promoter methylation may be a useful non-invasive biomarker for GC patients with MSI.
Discussion
GC remains a notable clinical challenge with an unfavorable prognosis. Cancer-related genes, such as tumor suppressor genes (TSGs), or DNA repair genes are commonly methylated in the promoter regions of CpG islands, which leads to the dysfunction or loss of gene expression, cancer initiation and progression [84, 85] . The absence or downregulation of MLH1 gene expression via promoter methylation was reported in GC [15, 32-34, 36, 37, 39, 42, 44-46, 50, 56, 59, 60, 62, 64, 72, 76, 77] . MLH1 promoter methylation is detected in some cancers, such as bladder cancer [86] , colorectal [87] and GC [18] . However, some studies reported that MLH1 promoter methylation exhibited a low frequency in GC [18, 34, 43, 44, 57, 65, 67, 70, 75, 78, 81] . Other studies reported that MLH1 promoter methylation exhibited a high frequency in GC [16, 33, 40, 62, [72] [73] [74] 80] . Therefore, we performed an integrated analysis to investigate whether MLH1 promoter methylation was a non-invasive biomarker that provided valuable insight for GC diagnosis and clinical outcome and a novel therapeutic target for GC. Our results from the data of more articles with larger study populations suggest that MLH1 promoter methylation is notably higher in GC than in gastric adenomas (OR = 2.44, P = 0.003), chronic gastritis (OR = 8.78, P < 0.001), adjacent (OR = 5.50, P < 0.001) and normal tissue samples (OR = 8.06, P = 0.011). MLH1 promoter methylation exhibited similar levels in GC vs. intestinal metaplasia and dysplasia. We demonstrated a specific methylation profile of the MLH1 gene during gastric carcinogenesis, from adenoma/chronic gastritis to GC. MLH1 promoter methylation may play a role in the malignant transformation of gastric precancerous lesions (adenoma and chronic gastritis).
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Eligible studies with larger sample sizes revealed that MLH1 promoter methylation was not associated with tumor histology, gender, H. pylori infection, smoking, or drinking behaviors of GC patients. MLH1 promoter methylation was also not associated with tumor differentiation, clinical stage, lymph node status, distant metastasis, or OS, which indicated that MLH1 promoter methylation did not play a key role in the progression, metastasis, or prognosis of GC. Hong et al. [54] . observed an association between MLH1 promoter methylation and age, but other studies reported no correlation [19, 36, 40, 41, 47, 48, 55, 64, 66, 78, 82, 83] . Twenty studies reported that MLH1 promoter methylation significantly correlated with microsatellite status [15, 30, 33, 37, 39-46, 51, 52, 55, 56, 60, 62, 63, 79] , but three studies demonstrated no association [57, 64, 76] . Our study revealed that MLH1 promoter methylation correlated with age and microsatellite status, and it was notably higher in patients 60 years of age or older than in patients younger than 60 years and higher in patients with MSI than in patients with MSS. These results suggest that MLH1 promoter methylation plays a more important role in elderly GC patients and GC patients with MSI.
Some studies suggested DNA methylation as a promising tool for the diagnosis of cancer [88] [89] [90] [91] . We analyzed the diagnostic effect of MLH1 promoter methylation in GC for the results with significant OR values and found that MLH1 promoter methylation could not distinguish GC from adjacent tissues, gastric adenomas, chronic gastritis, normal gastric mucosa, or normal healthy blood samples (i.e., the poor sensitivity value of < 0.5). The existence of cell-free circulating tumor DNA (ctDNA) was found in blood samples, and the presence of promoter methylation of tumor-related genes was examined in the cirDNA in many cancers [92] . Only Kolesnikova et al. reported the existence of ctDNA and MLH1 promoter methylation in blood samples of GC, with a frequency of 25% in GCs and a frequency of 9% in healthy subjects [83] . The combination of p15 and MLH1 promoter methylation in ctDNA exhibited a sensitivity of 65% and specificity of 72% [83] , which suggests that the combination of these two genes may significantly contribute to the diagnosis of GC. More studies are needed to analyze the diagnostic effect of tumor DNA circulating in the blood of GC patients to improve Several limitations should be considered in this study. First, there was substantial heterogeneity in GC vs. adjacent tissues and gender, and seven studies [31, 40, 61, 62, 68, 73, 74] were removed in the comparison of GC and adjacent tissue samples. Three studies [47, 54, 73] were excluded in relation to gender. The pooled results were not significantly changed, with no evidence of heterogeneity, which indicates the stability of our analyses. Second, publication bias was measured in GC vs. adjacent tissue samples and tumor histology. We searched the relevant databases to minimize the possible publication bias as completely as possible, but positive results are more easily published than negative results. Only articles published in the English language were selected, and articles in languages other than English were excluded. Third, sample sizes for the comparison between GC and benign lesions and GC and normal controls were not very large. Finally, sample sizes of subgroup analyses of mixed populations and non-MSP method were small.
Conclusion
Our results suggest that MLH1 promoter methylation exhibits a significantly higher frequency in GC than gastric adenoma, chronic gastritis, adjacent tissues, normal gastric mucosa, and normal healthy blood samples but a similar rate in GC and intestinal metaplasia and dysplasia. MLH1 promoter methylation correlated with age and the MSI of GC patients, but it was not associated with H. pylori infection, gender, smoking, drinking behaviors, tumor histology, tumor differentiation, clinical stage, lymph node status, distant metastasis, or the OS of GC patients. The use of MLH1 promoter methylation may be a potential prognostic biomarker for GC patients with MSI. More well-designed prospective trials are necessary to further validate our findings.
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